Inhaled insulin Afrezza approved by FDA

UPI Health News (Business) |

The U.S. Food and Drug Administration on Friday announced the approval of Afrezza, an inhaled insulin used in the treatment of diabetes.

The rapid-acting medicine can be used at the beginning of a meal or within 20 minutes after the start of a meal to control glycemic levels in adults with diabetes.



"Afrezza is a new treatment option for patients with diabetes requiring mealtime insulin," said Dr. Jean-Marc Guettier, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "Today's approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels."

The drug was tested in 3,017 patients, 1,026 with type 1 diabetes and 1,991 with type 2. The FDA said Afrezza was not a substitute for long-acting insulin and must be used in combination with long-acting insulin for patients with type 1 diabetes.

It also can't be used to treat diabetec ketoacidosis or by patients who smoke. The drug is manufactured by MannKind Corporation out of Danbury, Conn.

Some 25.8 million people in the United States have diabetes, which is about 8.3 percent of the total population.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ZMBAY Zambia Natl C/Bk Uns/Adr n/a n/a n/a 0

Comments

Emerging Growth

Broadway Gold Mining Ltd.

Broadway Gold Mining Ltd is engaged in the exploration of mineral resources. The Company owns a 100% interest in the Madison Gold and Copper Mine located in Southwestern Montana.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.